Superior vena cava syndrome epidemiology and demographics: Difference between revisions
(Mahshid) |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Superior vena cava syndrome is a common oncologic emergency. The [[incidence]] rate in the United States is approximately 15,000 individuals each year. The incidence of superior vena cava syndrome increases with age; the median age of diagnosis is between 40-60 years. Males are more commonly affected with superior vena cava syndrome than females. | [[Superior vena cava syndrome]] is a common [[Oncologic emergencies|oncologic emergency]]. The [[incidence]] rate in the United States is approximately 15,000 individuals each year. The [[incidence]] of [[superior vena cava syndrome]] increases with age; the median age of diagnosis is between 40-60 years. [[Male|Males]] are more commonly affected with superior vena cava syndrome than [[Female|females]]. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
| Line 10: | Line 10: | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of superior vena cava syndrome remains unknown.<ref name="pmid17168344">{{cite journal |vauthors=Higdon ML, Higdon JA |title=Treatment of oncologic emergencies |journal=Am Fam Physician |volume=74 |issue=11 |pages=1873–80 |year=2006 |pmid=17168344 |doi= |url=}}</ref> | *The [[prevalence]] of [[superior vena cava syndrome]] remains unknown.<ref name="pmid17168344">{{cite journal |vauthors=Higdon ML, Higdon JA |title=Treatment of oncologic emergencies |journal=Am Fam Physician |volume=74 |issue=11 |pages=1873–80 |year=2006 |pmid=17168344 |doi= |url=}}</ref> | ||
===Incidence=== | ===Incidence=== | ||
*In the United States, the incidence of superior vena cava syndrome is 15,000 individuals each year.<ref name="pmid17168344">{{cite journal |vauthors=Higdon ML, Higdon JA |title=Treatment of oncologic emergencies |journal=Am Fam Physician |volume=74 |issue=11 |pages=1873–80 |year=2006 |pmid=17168344 |doi= |url=}}</ref> | *In the United States, the [[incidence]] of superior vena cava syndrome is 15,000 individuals each year.<ref name="pmid17168344">{{cite journal |vauthors=Higdon ML, Higdon JA |title=Treatment of oncologic emergencies |journal=Am Fam Physician |volume=74 |issue=11 |pages=1873–80 |year=2006 |pmid=17168344 |doi= |url=}}</ref> | ||
===Gender=== | ===Gender=== | ||
*Males are more commonly affected with superior vena cava syndrome than females due to the higher incidence of lung cancer among males.<ref name="pmid25803363">{{cite journal |vauthors=Carter BW, Erasmus JJ |title=Acute Thoracic Findings in Oncologic Patients |journal=J Thorac Imaging |volume=30 |issue=4 |pages=233–46 |year=2015 |pmid=25803363 |doi=10.1097/RTI.0000000000000148 |url=}}</ref> | *[[Male|Males]] are more commonly affected with [[superior vena cava syndrome]] than [[Female|females]] due to the higher [[incidence]] of [[lung cancer]] among [[Male|males]].<ref name="pmid25803363">{{cite journal |vauthors=Carter BW, Erasmus JJ |title=Acute Thoracic Findings in Oncologic Patients |journal=J Thorac Imaging |volume=30 |issue=4 |pages=233–46 |year=2015 |pmid=25803363 |doi=10.1097/RTI.0000000000000148 |url=}}</ref> | ||
===Race=== | ===Race=== | ||
*The prevalence of SVCS does not vary by race. However, depending on the type of cancer a racial predilection may be possible.<ref name="pmid17168344">{{cite journal |vauthors=Higdon ML, Higdon JA |title=Treatment of oncologic emergencies |journal=Am Fam Physician |volume=74 |issue=11 |pages=1873–80 |year=2006 |pmid=17168344 |doi= |url=}}</ref> | *The [[prevalence]] of SVCS does not vary by race. However, depending on the type of [[cancer]] a [[Racial|racial predilection]] may be possible.<ref name="pmid17168344">{{cite journal |vauthors=Higdon ML, Higdon JA |title=Treatment of oncologic emergencies |journal=Am Fam Physician |volume=74 |issue=11 |pages=1873–80 |year=2006 |pmid=17168344 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 13:36, 12 April 2019
|
Superior Vena Cava Syndrome Microchapters |
|
Differentiating Superior Vena Cava Syndrome from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Superior vena cava syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Superior vena cava syndrome epidemiology and demographics |
|
FDA on Superior vena cava syndrome epidemiology and demographics |
|
CDC on Superior vena cava syndrome epidemiology and demographics |
|
Superior vena cava syndrome epidemiology and demographics in the news |
|
Blogs on Superior vena cava syndrome epidemiology and demographics |
|
Directions to Hospitals Treating Superior vena cava syndrome |
|
Risk calculators and risk factors for Superior vena cava syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Superior vena cava syndrome is a common oncologic emergency. The incidence rate in the United States is approximately 15,000 individuals each year. The incidence of superior vena cava syndrome increases with age; the median age of diagnosis is between 40-60 years. Males are more commonly affected with superior vena cava syndrome than females.
Epidemiology and Demographics
Prevalence
- The prevalence of superior vena cava syndrome remains unknown.[1]
Incidence
- In the United States, the incidence of superior vena cava syndrome is 15,000 individuals each year.[1]
Gender
- Males are more commonly affected with superior vena cava syndrome than females due to the higher incidence of lung cancer among males.[2]
Race
- The prevalence of SVCS does not vary by race. However, depending on the type of cancer a racial predilection may be possible.[1]